J Biomed Nanotechnol:纳米非晶硅氧磷化物(SiONP)覆盖层快速再生血管化骨

2019-05-26 不详 网络

骨折愈合是一个复杂的生物过程。创伤性骨折导致的严重骨丢失和缺血导致炎症和有害活性氧(ROS)的积累。固定装置不仅提供机械支持而且还刺激抗氧化剂如超氧化物歧化酶(SOD1)并影响细胞外基质(ECM)矿化的信号通路,对于这种骨折的正常愈合至关重要。在这项研究中,我们报告了一种新型生物材料,氧氮化硅(SiONP),在生理条件下数周内可提供离子硅(Si + 4)和磷(P)的持续释放。Si + 4的抗氧化作

骨折愈合是一个复杂的生物过程。创伤性骨折导致的严重骨丢失和缺血导致炎症和有害活性氧(ROS)的积累。固定装置不仅提供机械支持而且还刺激抗氧化剂如超氧化物歧化酶(SOD1)并影响细胞外基质(ECM)矿化的信号通路,对于这种骨折的正常愈合至关重要。

在这项研究中,我们报告了一种新型生物材料,氧氮化硅(SiONP),在生理条件下数周内可提供离子硅(Si + 4)和磷(P)的持续释放。Si + 4的抗氧化作用和P离子增强的ECM矿化导致增强的成骨作用以及快速血运重建以快速骨再生。等离子体增强化学气相沉积(PECVD)提供了覆盖在纳米制造的生物激发表面上的保形,良好粘附和高度可再现的表面化学。观察到氮与P和O的含量比改变了重叠膜的溶解速率和释放动力学。具有最佳释放动力学的SiONP薄膜通过增强的SOD1促进抗氧化表达,SOD1下游用MC3T3-E1细胞上调其他成骨标志物。通过人脐静脉内皮细胞(HUVEC)形成较厚的小管,这些表面也促进血管生成。

使用大鼠临界尺寸颅骨缺损模型进行的体内评估显示,与对照组相比,这些纳米制造生物材料的骨再生快速,并为未来临床试验开辟了新的视野,可用于生物医学设备的新抗氧化材料,可缩短愈合时间,降低医疗保健费用,并提高临界尺寸缺陷新生骨质量。

原始出处:

Ilyas A, Velton M, et al., Rapid Regeneration of Vascularized Bone by Nanofabricated Amorphous Silicon Oxynitrophosphide (SiONP) Overlays. J Biomed Nanotechnol. 2019 Jun 1;15(6):1241-1255. doi: 10.1166/jbn.2019.2779.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1644307, encodeId=85de164430e8d, content=<a href='/topic/show?id=b3c58958013' target=_blank style='color:#2F92EE;'>#血管化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89580, encryptionId=b3c58958013, topicName=血管化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Mar 07 12:44:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918714, encodeId=87531918e14fd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 29 01:44:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652341, encodeId=e96a1652341e7, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Feb 23 03:44:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609793, encodeId=ae1e1609e9306, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue May 28 12:44:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1644307, encodeId=85de164430e8d, content=<a href='/topic/show?id=b3c58958013' target=_blank style='color:#2F92EE;'>#血管化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89580, encryptionId=b3c58958013, topicName=血管化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Mar 07 12:44:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918714, encodeId=87531918e14fd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 29 01:44:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652341, encodeId=e96a1652341e7, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Feb 23 03:44:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609793, encodeId=ae1e1609e9306, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue May 28 12:44:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
    2019-07-29 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1644307, encodeId=85de164430e8d, content=<a href='/topic/show?id=b3c58958013' target=_blank style='color:#2F92EE;'>#血管化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89580, encryptionId=b3c58958013, topicName=血管化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Mar 07 12:44:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918714, encodeId=87531918e14fd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 29 01:44:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652341, encodeId=e96a1652341e7, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Feb 23 03:44:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609793, encodeId=ae1e1609e9306, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue May 28 12:44:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
    2020-02-23 shock_melon
  4. [GetPortalCommentsPageByObjectIdResponse(id=1644307, encodeId=85de164430e8d, content=<a href='/topic/show?id=b3c58958013' target=_blank style='color:#2F92EE;'>#血管化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89580, encryptionId=b3c58958013, topicName=血管化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Mar 07 12:44:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918714, encodeId=87531918e14fd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 29 01:44:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652341, encodeId=e96a1652341e7, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Feb 23 03:44:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609793, encodeId=ae1e1609e9306, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue May 28 12:44:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]